Having trouble accessing articles? Reset your cache.

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

Anti-glycan mAb licensed by BioNTech could prevent pancreatitis
A Science study from Cold Spring Harbor Laboratory suggests the glycan CA19.9 (sialyl Lewis A), long known as a biomarker

Read the full 276 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers